Deargen
AI-First Pharmatech Company. We are exploring sequence-based drug discovery and development.
11 employees · est. 2016 · Daejeon, Korea South
InterAx Biotech
Advanced integration of biological systems, math models and artificial intelligence
17 employees · est. 2016 · Switzerland
Side-by-Side Comparison
| Metric | Deargen | InterAx Biotech |
|---|---|---|
| Founded | ||
| Founded | 2016 | 2016 |
| Headquarters | ||
| Headquarters | Daejeon, Korea South | Switzerland |
| Employees | ||
| Employees | 11 | 17 |
| Industry | ||
| Industry | AI, Biotechnology, Machine Learning | AI, Biopharma, Biotechnology |
| Funding Stage | ||
| Funding Stage | Series B | Series A |
| Total Funding | ||
| Total Funding | $23.00B | $3.20M |
| Funding Rounds | ||
| Funding Rounds | 3 | 7 |
| Services | ||
| Services | AI Platform for Drug Discovery, New Drug Development, Molecular Optimization, Target Affinity Prediction, Toxicity-Centered Drug Design | Deep Signal™ Platform, Mechanistic Models for Drug Development, Pipeline of Drug Candidates |
| Target Customers | ||
| Target Customers | Pharmaceutical Companies, Biotech Firms, Medical Research Institutions, Drug Development Organizations, AI-Driven Healthcare Providers | Pharmaceutical Companies, Biotechnology Researchers, Clinical Development Teams |
| Taxonomy | ||
| Taxonomy | AI-driven Drug Discovery, Sequence-based Drug Development, Transformer Technology In Pharmaceuticals, Hit/Lead Compound Discovery, End-to-end AI Solution, Biotechnology Innovation, Genome Analysis Service, Deep Learning In Pharma, Computational Chemistry, Medicinal Chemistry, Target Discovery, Lead Optimization, AI In Healthcare, Pharmatech Innovation, Drug Design And Development | Biological Systems Integration, Mathematical Models, Drug Discovery, GPCR Drug Discovery, Biochemical Screening, Cell Pathways Modeling, Signaling Pathways, Cellular Pharmacology, Computational Chemistry, Hit Generation, Hit-to-Lead, Lead Optimization, Orphan GPCRs, High Throughput Screening |
| Website | ||
| Website | deargen.me | interaxbiotech.com |
About Deargen
Deargen, founded in 2016, positions itself as a pioneer in the intersection of AI and pharmaceuticals. This AI-First Pharmatech Company focuses on revolutionizing drug discovery and development through sequence-based AI solutions. Headquartered in Korea South, the company leverages advanced AI, part...
About InterAx Biotech
InterAx Biotech, founded in 2016, is a pioneering spin-out from ETH Zurich and the Paul Scherrer Institute in Switzerland. The company is at the forefront of integrating biological systems with advanced mathematical models and artificial intelligence, as highlighted in their slogan: "Advanced integr...
We will tell you when either one moves
BounceWatch watches Deargen and InterAx Biotech for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Deargen and InterAx Biotech — by email.
Frequently Asked Questions
Compare Deargen with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at Deargen on 15 Jun 2026, and InterAx Biotech on 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.